Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sambucus Ebulus Extract Stimulates Cellular Responses in Cutaneous Leishmaniasis Publisher Pubmed



Heidarikharaji M1 ; Fallahomrani V2 ; Badirzadeh A3 ; Mohammadighalehbin B4 ; Nilforoushzadeh MA1 ; Masoori L3 ; Montakhabyeganeh H5 ; Zare M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Microbiology and Medical Parasitology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
  5. 5. Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Source: Parasite Immunology Published:2019


Abstract

This is the first study aiming to determine the therapeutic effects of the Sambucus ebulus aquatic extract as an antileishmanial herbal drug and evaluate the immune responses in Leishmania major major infected BALB/c mice. The antileishmanial activity of S ebulus aquatic extract was evaluated using MTT test as well as parasite rescue and transformation assay. Footpad swelling and parasite load of infected mice were measured by several techniques. The immune responses were evaluated by measuring the levels of IFN-γ, IL-4, nitric oxide and arginase. The results indicated that S. ebulus can significantly decrease L. major promastigotes and amastigotes viability, but it was not toxic to macrophages. The lesion size, parasite burden and the level of ARG decreased in the treated infected mice, while the IFN-γ-to-IL-4 ratio and the level of NO increased significantly. Altogether, the S. ebulus extract is an effective compound for killing Leishmania parasite without excessive toxicity to the host cells and can cure the CL by switching the host immune responses towards Th1 response. Thus, it may be a perfect therapeutic option for CL treatment. © 2018 John Wiley & Sons Ltd
Other Related Docs
14. Development of a Topical Liposomal Formulation of Amphotericin B for the Treatment of Cutaneous Leishmaniasis, International Journal for Parasitology: Drugs and Drug Resistance (2019)
44. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)